CA2037353A1 - Mode d'auto-administration d'un agoniste des recepteurs dopaminergiques d2 - Google Patents
Mode d'auto-administration d'un agoniste des recepteurs dopaminergiques d2Info
- Publication number
- CA2037353A1 CA2037353A1 CA002037353A CA2037353A CA2037353A1 CA 2037353 A1 CA2037353 A1 CA 2037353A1 CA 002037353 A CA002037353 A CA 002037353A CA 2037353 A CA2037353 A CA 2037353A CA 2037353 A1 CA2037353 A1 CA 2037353A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- dopamine
- range
- craving
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 title claims abstract description 35
- 235000019788 craving Nutrition 0.000 claims abstract description 62
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical group C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims abstract description 47
- 229960002802 bromocriptine Drugs 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 40
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 30
- 230000001186 cumulative effect Effects 0.000 claims abstract description 24
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 23
- 229960002715 nicotine Drugs 0.000 claims abstract description 23
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960003920 cocaine Drugs 0.000 claims abstract description 15
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 230000004044 response Effects 0.000 claims description 31
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 230000000391 smoking effect Effects 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 4
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 2
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 2
- 239000004571 lime Substances 0.000 claims description 2
- 229940098778 Dopamine receptor agonist Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 126
- 229960003638 dopamine Drugs 0.000 abstract description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 9
- 239000000021 stimulant Substances 0.000 abstract description 7
- 208000011117 substance-related disease Diseases 0.000 abstract description 6
- 201000009032 substance abuse Diseases 0.000 abstract description 5
- 231100000736 substance abuse Toxicity 0.000 abstract description 4
- 206010012335 Dependence Diseases 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 30
- 239000003814 drug Substances 0.000 description 30
- 101150049660 DRD2 gene Proteins 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 5
- 235000019504 cigarettes Nutrition 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 229960004046 apomorphine Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229950007886 lergotrile Drugs 0.000 description 3
- JKAHWGPTNVUTNB-IXPVHAAZSA-N lergotrile Chemical compound C1=CC([C@H]2C[C@@H](CC#N)CN([C@@H]2C2)C)=C3C2=C(Cl)NC3=C1 JKAHWGPTNVUTNB-IXPVHAAZSA-N 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000009103 reabsorption Effects 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940025084 amphetamine Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 229960003587 lisuride Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 229960004851 pergolide Drugs 0.000 description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 101150048818 Faim gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229940015769 nicotine chewing gum Drugs 0.000 description 1
- 229940000596 parlodel Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63348590A | 1990-12-27 | 1990-12-27 | |
| US07/633,485 | 1990-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2037353A1 true CA2037353A1 (fr) | 1992-06-28 |
Family
ID=24539823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002037353A Abandoned CA2037353A1 (fr) | 1990-12-27 | 1991-02-28 | Mode d'auto-administration d'un agoniste des recepteurs dopaminergiques d2 |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2037353A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001848A (en) * | 1996-03-25 | 1999-12-14 | The Regents Of The University Of California | Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele |
-
1991
- 1991-02-28 CA CA002037353A patent/CA2037353A1/fr not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001848A (en) * | 1996-03-25 | 1999-12-14 | The Regents Of The University Of California | Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6893654B2 (en) | Two-stage transmucosal medicine delivery system for symptom relief | |
| US5861422A (en) | Agonist-antagonist combination to reduce the use of nicotine and other drugs | |
| US5783207A (en) | Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine | |
| Hanson et al. | Nicotine self-administration in rats | |
| JPH11505547A (ja) | ナルトレキソン及び関連化合物を用いる禁煙処置 | |
| RU2262352C2 (ru) | Применение агонистов рецепторов b-типа гамма-аминомасляной кислоты и их фармацевтически приемлемых производных при лечении никотиновой зависимости | |
| US4800204A (en) | Method of controlling tobacco use | |
| WO1995007690A1 (fr) | Composition et procede destines a traiter le besoin de nicotine chez les personnes qui cessent de fumer | |
| AU782403B2 (en) | Method for reducing or eliminating smoking | |
| WO2008124814A2 (fr) | Formulations sublinguales de d-cyclosérine et leurs procédés d'utilisation | |
| Jarvik et al. | Pharmacological adjuncts for the treatment of tobacco dependence | |
| US5414005A (en) | Methods and articles of manufacture for the treatment of nicotine withdrawal and as an aid in smoking cessation | |
| Dale et al. | Drug therapy to aid in smoking cessation: tips on maximizing patients' chances for success | |
| WO1990000896A1 (fr) | EMPLOI DE BENZO(g)QUINOLEINES DANS LE TRAITEMENT DE L'ACCOUTUMANCE A LA NICOTINE | |
| CA2037353A1 (fr) | Mode d'auto-administration d'un agoniste des recepteurs dopaminergiques d2 | |
| CA2174747A1 (fr) | Utilisation de la lobeline dans le traitement de symptomes de sevrage de nicotine | |
| WO2022120444A1 (fr) | Implant sous-cutané réabsorbable de longue durée à libération prolongée de substance pharmacologiquement active pré-concentrée en polymère pour le traitement de la dépendance à la nicotine et procédé | |
| DENELSKY | Pharmacologic aids to smoking cessation | |
| WO1995011678A9 (fr) | Utilisation de substituts de nicotine pour le traitement du sevrage a la nicotine | |
| RU2146942C1 (ru) | Способ лечения табакокурения | |
| Gautam et al. | Evaluation of pharmacological and non–pharmacological methods of smoking cessation: A Review | |
| GB2204240A (en) | Anti-smoking compositions | |
| Rose | Transdermal Nicotine and Nasal Nicotine Administration as Smoking-Cessation Treatments | |
| CA2132209A1 (fr) | Combinaisons d'agents parasympathomimetiques et d'antagonistes muscariniques pour le traitement de la dependance a la nicotine en vue de l'arret du tabagisme | |
| Climko | Anticholinergics and Other Medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 19940831 |